Beam Therapeutics Q3 Earnings Forecast Cut by HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings estimates for Beam Therapeutics in a report issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.26) for the quarter, down from their prior forecast of ($1.25). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.49) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2026 earnings at ($1.32) EPS, FY2026 earnings at ($4.67) EPS, Q1 2027 earnings at ($1.28) EPS, Q2 2027 earnings at ($1.30) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at ($1.30) EPS, FY2027 earnings at ($5.23) EPS, FY2028 earnings at ($4.39) EPS, FY2029 earnings at ($3.04) EPS and FY2030 earnings at ($1.48) EPS.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.07). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $16.37 million. Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%. The business’s revenue for the quarter was down 94.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.00) earnings per share.

BEAM has been the subject of several other research reports. Wedbush reduced their price objective on shares of Beam Therapeutics from $65.00 to $28.00 and set an “outperform” rating for the company in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Beam Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. William Blair raised shares of Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Bank of America reissued a “buy” rating and set a $47.00 target price on shares of Beam Therapeutics in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.40.

Beam Therapeutics Price Performance

Shares of Beam Therapeutics stock opened at $28.78 on Thursday. Beam Therapeutics has a 52 week low of $20.23 and a 52 week high of $38.26. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2.97 billion, a PE ratio of -33.46 and a beta of 2.20. The company’s 50-day moving average price is $25.96 and its two-hundred day moving average price is $28.21.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds have recently modified their holdings of BEAM. SBI Securities Co. Ltd. boosted its position in shares of Beam Therapeutics by 15.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 4,572 shares of the company’s stock valued at $112,000 after purchasing an additional 618 shares during the period. Versant Capital Management Inc raised its holdings in Beam Therapeutics by 123.6% during the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock worth $30,000 after buying an additional 685 shares during the period. Swiss National Bank raised its holdings in Beam Therapeutics by 0.6% during the 1st quarter. Swiss National Bank now owns 180,600 shares of the company’s stock worth $4,304,000 after buying an additional 1,100 shares during the period. Royal Bank of Canada raised its holdings in Beam Therapeutics by 7.3% during the 1st quarter. Royal Bank of Canada now owns 16,825 shares of the company’s stock worth $401,000 after buying an additional 1,144 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Beam Therapeutics by 1,372.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,252 shares of the company’s stock valued at $43,000 after buying an additional 1,167 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO John Evans sold 25,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer directly owned 1,047,205 shares of the company’s stock, valued at $24,682,621.85. The trade was a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.80% of the stock is owned by company insiders.

Trending Headlines about Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Initial Phase 1/2 data provided proof of concept for BEAM-301: two patients in the 40 mg cohort achieved 15 hours of controlled fasting, showed improved glucose control and no longer required starch supplementation. The reported safety profile was consistent with other lipid-nanoparticle therapies. Beam Therapeutics BEAM-301 clinical data
• Positive Sentiment: Beam plans to discuss a potential regulatory path with the FDA, while enrollment in the 60 mg cohort is underway. A successful one-time treatment could represent a significant commercial opportunity in the rare-disease market. MarketScreener BEAM-301 clinical data
• Positive Sentiment: H.C. Wainwright reportedly viewed the early BEAM-301 results as supporting substantial additional upside, helping reinforce bullish sentiment around Beam’s gene-editing platform. Stocktwits report on BEAM-301 and H.C. Wainwright outlook
• Negative Sentiment: Wedbush cut its price target for BEAM sharply from $65 to $28, citing a much lower valuation ceiling despite maintaining an “Outperform” rating. The new target suggests limited near-term upside based on the quoted share price. Wedbush lowers Beam Therapeutics price target

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.